iguratimod 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
immunomodulators, both stimulant/suppressive and stimulant	4894	123663-49-0

Description:

Molecule

Description

Molfile Inchi Smiles

Synonyms:

iguratimod
kolbet
careram
T-614

a methanesulfonanilide disease-modifying antirheumatic drug that has been developed exclusively in Japan and China

Molecular weight: 374.37
Formula: C17H14N2O6S
CLOGP: 1.63
LIPINSKI: 0
HAC: 8
HDO: 2
TPSA: 110.80
ALOGS: -3.75
ROTB: 4

Drug dosage:

None

ADMET properties:

None

Approvals:

Date	Agency	Company	Orphan
June 29, 2012	PMDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Pneumocystis jirovecii pneumonia	168.09	46.76	40	811	16874	63471297
Interstitial lung disease	89.99	46.76	33	818	61875	63426296
Lymphoproliferative disorder	84.97	46.76	17	834	3173	63484998
Adult T-cell lymphoma/leukaemia	63.06	46.76	9	842	216	63487955

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Interstitial lung disease	75.23	55.56	24	197	65258	34891452

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Pneumocystis jirovecii pneumonia	162.96	40.83	46	1191	32462	79710689
Interstitial lung disease	137.64	40.83	55	1182	112545	79630606
Lymphoproliferative disorder	122.53	40.83	26	1211	5589	79737562
Adult T-cell lymphoma/leukaemia	58.02	40.83	9	1228	331	79742820
Pneumonia bacterial	52.05	40.83	17	1220	19314	79723837
Herpes zoster	47.96	40.83	25	1212	93058	79650093

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

None

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Rheumatoid arthritis	indication	69896004	DOID:7148

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	6.64	acidic
pKa2	9.55	acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Macrophage migration inhibitory factor	Unclassified	P14174	MIF_HUMAN		IC50	5.17		CHEMBL

External reference:

ID	Source
4IHY34Y2NV	UNII
D01146	KEGG_DRUG
C1872427	UMLSCUI
CHEBI:31689	CHEBI
CHEMBL2107455	ChEMBL_ID
124246	PUBCHEM_CID
DB12233	DRUGBANK_ID
8176	INN_ID
C519076	MESH_SUPPLEMENTAL_RECORD_UI
C077313	MESH_SUPPLEMENTAL_RECORD_UI
9736	IUPHAR_LIGAND_ID

Pharmaceutical products:

None